Can analysts adopt a bullish outlook for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)?

June 17, 2018 - By Migdalia James

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Ratings Coverage

Among 6 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 7 analyst reports since December 20, 2017 according to SRatingsIntel. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has “Buy” rating given on Tuesday, February 13 by H.C. Wainwright. JMP Securities maintained Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on Monday, March 19 with “Buy” rating. The company was maintained on Wednesday, December 20 by H.C. Wainwright. Below is a list of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) latest ratings and price target changes.

04/05/2018 Broker: Cowen & Co Rating: Outperform Initiates Coverage On
19/03/2018 Broker: JMP Securities Rating: Buy New Target: $9.0 Maintain
19/03/2018 Broker: Evercore Rating: Outperform New Target: $13 Initiates Coverage On
19/03/2018 Broker: Jefferies Rating: Buy New Target: $12 Initiates Coverage On
13/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
17/01/2018 Broker: William Blair Rating: Outperform Initiates Coverage On
20/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain

The stock decreased 2.82% or $0.15 during the last trading session, reaching $5.17. About 652,177 shares traded or 17.62% up from the average. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 40.22% since June 17, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $279.05 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: